Completed PHASE2 INTERVENTIONAL NCT00002969

S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase II Trial of Paclitaxel by 96-Hour Infusion in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)

Sponsor: National Cancer Institute (NCI)

Interventions paclitaxel

Updated 7 times since 2017 Last updated: Jul 20, 2012 Started: May 31, 1997 Primary completion: Jan 31, 2004 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002969, this PHASE2 trial focuses on Lung Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 1997, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2023 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
SWOG Cancer Research Network

Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Atlanta, United States , Billings, United States , Biloxi, United States , Boston, United States , Brooklyn, United States , Cincinnati, United States , Cleveland, United States , Columbus, United States and 46 more locations